Background. To determine the effects of etidronate (a bisphosphonate that inhibits
osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we …

ContextRisedronate, a potent bisphosphonate, has been shown to be effective in the treatment
of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it …

Objective: The aim was to formulate practice guidelines for management of osteoporosis in
men. Evidence: We used the Grading of Recommendations, Assessment, Development, and …

Osteoporosis is a growing major public health problem with impact that crosses medical,
social, and economic lines. These guidelines have been developed by the American …

… Nelson B Watts Nelson B Watts … or proteins that are secreted by cells involved in the
remodeling process, (b) breakdown products generated in the resorption of old bone, and (c) …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the …

BMD and clinical risk factors predict hip and other osteoporotic fractures. The combination
of clinical risk factors and BMD provide higher specificity and sensitivity than either alone. …

ContextIn the Women's Health Initiative trial of estrogen-plus-progestin therapy, women
assigned to active treatment had fewer fractures.ObjectiveTo test the hypothesis that the relative …

… *Address all correspondence and requests for reprints to: Nelson B. Watts, MD, University
of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Road, Suite 6300, …

purpose: To determine the effect of long-term intermittent cyclic etidronate treatment on
spinal bone density and vertebral fracture rates. patients and methods: Postmenopausal …